FIGURE 5 from An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
Authors: Guyot Boris , Clément Flora , Drouet Youenn , Schmidt Xenia , Lefort Sylvain , Delay Emmanuel , Treilleux Isabelle , Foy Jean-Philippe , Jeanpierre Sandrine , Thomas Emilie , Kielbassa Janice , Tonon Laurie , Zhu Helen He , Saintigny Pierre , Gao Wei-Qiang , de la Fouchardiere Arnaud , Tirode Franck , Viari Alain , Blay Jean-Yves , Maguer-Satta Véronique 
Published: September 2023

<p>An increased ENI10 score predicts patient's survival in several cancer types. <b>A,</b> ssGSEA ENI10 score in pairs of normal and tumor samples from TCGA's Pan-Cancer atlas linked by gray lines and the difference are color coded on the dots representing the tumor samples. ACC: adrenocortical carcinoma, BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL: cholangiocarcinoma, COAD: colon adenocarcinoma, DLBC: lymphoid neoplasm diffuse large B-cell lymphoma, ESCA: esophageal carcinoma, HNSC: head and neck squamous cell carcinoma, KICH: kidney chromophobe, KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma, LAML: acute myeloid leukemia, LGG: low-grade glioma, LIHC: liver hepatocellular carcinoma, LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, MESO: mesothelioma, OV: ovarian cancer, PCPG: pheochromocytoma and paraganglioma, PRAD: prostate adenocarcinoma, READ: rectum adenocarcinoma, SARC: sarcoma, SKCM: skin cutaneous melanoma, STAD: stomach adenocarcinoma, TGCT: testicular germ cell tumor, THCA: thyroid carcinoma, THYM: thymoma, UCEC: uterine corpus endometrial carcinoma, UCS: uterine carcinosarcoma, UVM: uveal melanoma. <b>B,</b> Correlation of the ENI10 score and survival outcome for each type of cancer of TCGA Pan-Cancer atlas estimated by HRs of PFS corresponding to one SD of the score taken as a continuous variable. Dots show the HR and adjacent bars the 95% confidence interval. <b>C,</b> Examples of PFS curves from TCGA Pan-Cancer atlas in the whole cohort and as a function of stage estimated using the Kaplan–Meier method and compared with the log-rank test between groups of patients defined by the median of the ENI10 score (low scores in blue and high scores in red). <b>D,</b> ssGSEA ENI10 score in transcriptomic data from nevus or melanoma at different stage of clinically defined transformation. <b>E,</b> Using transcriptomic data from the “Genomics of drug sensitivity in cancer” project from the Sanger Institute, ENI10 score of all human cancers cell lines available were correlated with their IC<sub>50</sub> to 441 drugs. Targets of the drugs with a significative negative correlation between the ENI10 ssGSEA score and IC<sub>50</sub> (indicating a sensitivity to the drug when the ENI10 score increase) are shown. According to the GDSC guidelines, red dots show drugs with a significative IC<sub>50</sub> correlation with the ENI10 score with a <i>P</i> value inferior to 0.001 and a Benjamini–Hochberg FDR inferior to 0.25. Black dots show suggestive correlations with a <i>P</i> value inferior to 0.005 and a nonparametric <i>P</i> value inferior to 0.1.</p>